Search

Your search keyword '"Chartier, Loic"' showing total 29 results
Start Over Author "Chartier, Loic" Search Limiters Available in Library Collection
29 results on '"Chartier, Loic"'

1. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Author

Aubrais, Raphaelle, Bouabdallah, Krimo, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, and Damaj, Gandhi

Published
2023
Full Text
View/download PDF

2. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Author

Thieblemont, Catherine, Altmann, Bettina, Frontzek, Fabian, Renaud, Loïc, Chartier, Loic, Ketterer, Nicolas, Récher, Christian, Poeschel, Viola, Fitoussi, Olivier, Held, Gerhard, Casasnovas, Olivier, Haioun, Corinne, Morschhauser, Franck, Glass, Bertram, Mounier, Nicolas, Tilly, Herve, Rosenwald, Andreas, Ott, German, Lenz, Georg, Molina, Thierry, Ziepert, Marita, and Schmitz, Norbert

Published
2023
Full Text
View/download PDF

3. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

Author

Thieblemont, Catherine, Chartier, Loic, Dührsen, Ulrich, Vitolo, Umberto, Barrington, Sally F., Zaucha, Jan M., Vercellino, Laetitia, Gomes Silva, Maria, Patrocinio-Carvalho, Ines, Decazes, Pierre, Viailly, Pierre-Julien, Tilly, Herve, Berriolo-Riedinger, Alina, Casasnovas, Oliver, Hüttmann, Andreas, Ilyas, Hajira, Mikhaeel, N. George, Dunn, Joel, Cottereau, Anne-Ségolène, Schmitz, Christine, Kostakoglu, Lale, Paulson, Joseph N., Nielsen, Tina, and Meignan, Michael

Published
2022
Full Text
View/download PDF

4. Step-index optical fibre drawn from 3D printed preforms

Author

CooK, Kevin, Balle, Geoffrey, Canning, John, Chartier, Loic, Athanaze, Tristan, Hossain, Md Arafat, Han, Chunyang, Comatti, Jade-Edouard, Luo, Yanhua, and Peng, Gang-Ding

Subjects
Physics - Instrumentation and Detectors, Physics - Optics
Abstract

Optical fibre is drawn from a dual-head 3D printer fabricated preform made of two optically transparent plastics with a high index core (NA ~ 0.25, V > 60). The asymmetry observed in the fibre arises from asymmetry in the 3D printing process. The highly multi-mode optical fibre has losses measured by cut-back as low as {\alpha} ~ 0.44 dB/cm in the near IR., Comment: Submission date: to Optics Letters 17 July 2016

Published
2016

5. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort

Author

Ghesquières, Hervé, Rossi, Cédric, Cherblanc, Fanny, Le Guyader-Peyrou, Sandra, Bijou, Fontanet, Sujobert, Pierre, Fabbro-Peray, Pascale, Bernier, Adeline, Belot, Aurélien, Chartier, Loic, Fornecker, Luc-Matthieu, Baldi, Isabelle, Bouabdallah, Krimo, Laurent, Camille, Oberic, Lucie, Morineau, Nadine, Le Gouill, Steven, Morschhauser, Franck, Haioun, Corinne, Damaj, Gandhi, Guidez, Stéphanie, Labouré, Gaëlle, Fitoussi, Olivier, Lebras, Laure, Gressin, Rémy, Salles, Gilles, Ysebaert, Loïc, and Monnereau, Alain

Published
2021
Full Text
View/download PDF

6. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Author

Cottereau, Anne-Ségolène, Versari, Annibale, Loft, Annika, Casasnovas, Olivier, Bellei, Monica, Ricci, Romain, Bardet, Stéphane, Castagnoli, Antonio, Brice, Pauline, Raemaekers, John, Deau, Bénédicte, Fortpied, Catherine, Raveloarivahy, Tiana, Van Zele, Emelie, Chartier, Loic, Vander Borght, Thierry, Federico, Massimo, Hutchings, Martin, Ricardi, Umberto, Andre, Marc, and Meignan, Michel

Published
2018
Full Text
View/download PDF

7. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA

Author

Aubrais, Raphaelle, primary, Bouabdallah, Krimo, additional, chartier, loic, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Sibon, David, additional, Schiano, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, LE CALLOCH, Ronan, additional, bellal, Mathieu, additional, Delapierre, Baptiste, additional, daguindau, nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, besson, caroline, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie-Cécile, additional, and Damaj, Gandhi, additional

Published
2022
Full Text
View/download PDF

9. Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells

Author

Galtier, Jean, primary, Vercellino, Laetitia, additional, Chartier, Loic, additional, Olivier, Pierre, additional, Tabouret-Viaud, Claire, additional, Mesguich, Charles, additional, Di Blasi, Roberta, additional, Durand, Amandine, additional, Raffy, Léo, additional, Gros, François-Xavier, additional, Madelaine, Isabelle, additional, Meignin, Veronique, additional, Mebarki, Miryam, additional, Rubio, Marie-Thérèse, additional, Feugier, Pierre, additional, Casasnovas, Olivier, additional, Meignan, Michel, additional, and Thieblemont, Catherine, additional

Published
2022
Full Text
View/download PDF

10. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA

Author

Le Gouill, Steven, Ghesquieres, Hervé, Obéric, Lucie, Morschhauser, Franck, Tilly, Herve, Ribrag, Vincent, Lamy, Thierry, Thieblemont, Catherine, Maisonneuve, Herve Gerard, Gressin, Remy, Bouabdallah, Krimo, Haioun, Corinne, Damaj, Gandhi, Fornecker, Luc-Matthieu, Bouabdallah, Reda, Feugier, Pierre, Sibon, David, Cartron, Guillaume, Bonnet, Christophe, André, Marc, Chartier, Loic, Ruminy, Philippe, Kraeber-Bodere, F, Bodet-Milin, C, Berriolo-Riedinger, Alina, Briere, Josette, Jais, Jean-Philippe, Molina, Thierry, Itti, Emmanuel, Casasnovas, Olivier, Centre hospitalier universitaire de Nantes (CHU Nantes), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Institut Gustave Roussy (IGR), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Hôpital Michallon, CHU Pessac, CHI Créteil, Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Les Hôpitaux Universitaires de Strasbourg (HUS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Liège (CHU-Liège), CHU UCL Namur, The Lymphoma Academic Research Organisation [Lyon] (LYSARC), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Hopital Saint-Louis [AP-HP] (AP-HP), Université Paris Descartes - Paris 5 (UPD5), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Jonchère, Laurent, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
[SDV] Life Sciences [q-bio], [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV]Life Sciences [q-bio], [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Abstract

International audience; Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted International Prognostic Index (aaIPI) score ≥1 DLBCL were randomized (1:1) between obinutuzumab or rituximab and stratified by aaIPI (1; 2-3) and chemotherapy regimen (doxorubicin, cyclophosphamide, prednisone plus vindesine, bleomycin [ACVBP] or vincristine [CHOP]). Consolidation treatment was determined according to response to interim positron emission tomography (PET). Responders after cycle 2 and 4 (PET2-/PET4-) received immunochemotherapy. Responders after only cycle 4 (PET2+/4-) received transplantation. The primary objective was an 8% improvement (hazard ratio [HR] = 0.73; 80% power; α risk, 2.5%; 1-sided) in 2-year event-free survival (EFS) in the obinutuzumab arm. From September 2012, 670 patients were enrolled (obinutuzumab, n = 336; rituximab, n = 334). A total of 383 (57.2%) were aaIPI 2-3, 339 (50.6%) received CHOP. Median follow-up was 38.7 months. The 2-year EFS was similar in both groups (59.8% vs 56.6%; P = .123; HR = 0.88). The 2-year PFS in the whole cohort was 83.1% (95% confidence interval, 80% to 85.8%). PET2-/4- and PET2+/4- had similar 2-year progression-free survival (PFS) and overall survival (OS): 89.9% vs 83.9% and 94.8% vs 92.8%. The 2-year PFS and OS for PET4+ patients were 62% and 83.1%. Grade 3-5 infections were more frequent in the obinutuzumab arm (21% vs 12%). Obinutuzumab is not superior to rituximab in aaIPI ≥1 DLBCL transplant-eligible patients. This trial was registered at www.clinicaltrials.gov as #NCT01659099.

Published
2021

12. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Author

Le Gouill, Steven, primary, Ghesquières, Hervé, additional, Oberic, Lucie, additional, Morschhauser, Franck, additional, Tilly, Hervé, additional, Ribrag, Vincent, additional, Lamy, Thierry, additional, Thieblemont, Catherine, additional, Maisonneuve, Hervé, additional, Gressin, Rémy, additional, Bouhabdallah, Krimo, additional, Haioun, Corinne, additional, Damaj, Gandhi, additional, Fornecker, Luc, additional, Bouhabdallah, Réda, additional, Feugier, Pierre, additional, Sibon, David, additional, Cartron, Guillaume, additional, Bonnet, Christophe, additional, André, Marc, additional, Chartier, Loic, additional, Ruminy, Philippe, additional, Kraeber-Bodéré, Françoise, additional, Bodet-Milin, Caroline, additional, Berriolo-Riedinger, Alina, additional, Brière, Josette, additional, Jais, Jean-Philippe, additional, Molina, Thierry Jo, additional, Itti, Emmanuel, additional, and Casasnovas, René-Olivier, additional

Published
2021
Full Text
View/download PDF

13. Evaluation of the Roche Cobas TaqMan and Abbott realtime extraction-quantification system for HIV-1 subtypes

Author

Gueudin, Marie, Plantier, Jean Christophe, Lemee, Veronique, Schmitt, Marie Paule, Chartier, Loic, Bourlet, Thomas, Ruffault, Annick, Damond, Florence, Vray, Muriel, and Simon, Francois

Subjects
HIV infection -- Diagnosis, HIV infection -- Prevention, Polymerase chain reaction -- Observations, Viremia -- Measurement, Viremia -- Research, Health
Abstract

The Abbott Molecular RealTime and Roche Diagnostics Cobas Taqman automated nucleic acid extraction and real-time polymerase chain reaction (PCR) amplification systems are compared for their capacity to quantify HIV RNA of various subtypes. The analysis has shown that the limitation of real-time PCR to span the entire diversity of HIV should be considered during treatment monitoring, resistance studies and clinical trials.

Published
2007

14. High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Author

Vercellino, Laetitia, primary, Cottereau, Anne-Segolene, primary, Casasnovas, Olivier, primary, Tilly, Hervé, primary, Feugier, Pierre, primary, Chartier, Loic, primary, Fruchart, Christophe, primary, Roulin, Louise, primary, Oberic, Lucie, primary, Pica, Gian Matteo, primary, Ribrag, Vincent, primary, Abraham, Julie, primary, Simon, Marc, primary, Gonzalez, Hugo, primary, Bouabdallah, Reda, primary, Fitoussi, Olivier, primary, Sebban, Catherine, primary, López-Guillermo, Armando, primary, Sanhes, Laurence, primary, Morschhauser, Franck, primary, Trotman, Judith, primary, Corront, Bernadette, primary, Choufi, Bachra, primary, Snauwaert, Sylvia, primary, Godmer, Pascal, primary, Briere, Josette, primary, Salles, Gilles, primary, Gaulard, Philippe, primary, Meignan, Michel, primary, and Thieblemont, Catherine, primary

Published
2020
Full Text
View/download PDF

17. The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Author

Thieblemont, Catherine, Chartier, Loïc, Dührsen, Ulrich, Vitolo, Umberto, Barrington, Sally F, Vercellino, Laetitia, Zaucha, Jan, Patrocinio Carvalho, Inês, Maria, Gomes da Silva, Decazes, Pierre, Viailly, Pierre-Julien, Tilly, Herve, Berriolo-Riedinger, Alina, Casasnovas, Rene-Olivier, Hüttmann, Andreas, Ilyas, Hajira, Mikhaeel, George, Dunn, Joel, Cottereau, Anne Ségolène, Schmitz, Christine, Paulson, Joseph N., Nielsen, Tina G, and Meignan, Michel

Published
2020
Full Text
View/download PDF

18. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma

Author

Cottereau, Anne-Ségolène, primary, Hapdey, Sebastien, additional, Chartier, Loic, additional, Modzelewski, Romain, additional, Casasnovas, Olivier, additional, Itti, Emmanuel, additional, Tilly, Herve, additional, Vera, Pierre, additional, Meignan, Michel A., additional, and Becker, Stéphanie, additional

Published
2016
Full Text
View/download PDF

19. First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial

Author

Rossi, Cedric, Marouf, Amira, Deau Fischer, Benedicte, Cherblanc, Fanny, Cugnod, Emeline, Chartier, Loic, Fornecker, Luc Matthieu, Andre, Marc, Casasnovas, Rene-Olivier, and Ghesquieres, Herve

Abstract

Background: AHL2011, a randomized phase III trial demonstrated that PET-CT after two cycles of BEACOPP escalatedchemotherapy safely guided treatment of patients aged 16-60 years with newly diagnosed advanced classical Hodgkin lymphoma (cHL) and allowed the use of ABVD in early responders with reduced toxicities and no impaired disease control. REALYSA study, a real-life multicentric cohort set up in France since 2018, included 6000 newly diagnosed lymphoma patients with over 1000 cHL patients. In the present study, we investigated whether real-world data could reproduce results issued from a randomized phase III clinical trial using the propensity score approach.

Published
2023
Full Text
View/download PDF

20. Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study

Author

Cottereau, Anne Ségolène, Vercellino, Laetitia, Casasnovas, Olivier, Tilly, Herve, Feugier, Pierre, Fruchart, Christophe, Roulin, Louise, Oberic, Lucie, Pica, Gian Matteo, Ribrag, Vincent, Abraham, Julie, Simon, Marc, Gonzalez, Hugo, Bouabdallah, Reda, Fitoussi, Olivier, Sebban, Catherine, Lopez-Guillermo, Armando, Macro, Margaret, Sahnes, Laurence, Morschhauser, Franck, Trotman, Judith, Corront, Bernadette, Choufi, Bachra, Snauwaert, Sylvia, Godmer, Pascal, Chartier, Loïc, Salles, Gilles, Briere, Josette, Coiffier, Bertrand, Meignan, Michel, and Thieblemont, Catherine

Published
2018
Full Text
View/download PDF

21. Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B

Author

Maylin, Sarah, primary, Sire, Jean-Marie, additional, Mbaye, Papa Saliou, additional, Simon, François, additional, Sarr, Anna, additional, Evra, Marie-Louise, additional, Fall, Fatou, additional, Daveiga, Jean, additional, Diallo, Aboubakry, additional, Debonne, Jean-Marc, additional, Chartier, Loic, additional, and Vray, Muriel, additional

Published
2015
Full Text
View/download PDF

26. Predictors of Pneumocystosis or Tuberculosis in HIV-Infected Asian Patients With AFB Smear-Negative Sputum Pneumonia

Author

Minor, Odile Le, primary, Germani, Yves, additional, Chartier, Loic, additional, Lan, Nguyen Huu, additional, Lan, Nguyen T P, additional, Duc, Nguyen H, additional, Laureillard, Didier, additional, Fontanet, Arnaud, additional, Sar, Borann, additional, Saman, Manil, additional, Chan, Sarin, additional, L'Her, Pierre, additional, Mayaud, Charles, additional, and Vray, Muriel, additional

Published
2008
Full Text
View/download PDF

28. Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells.

Author

Galtier J, Vercellino L, Chartier L, Olivier P, Tabouret-Viaud C, Mesguich C, Di Blasi R, Durand A, Raffy L, Gros FX, Madelaine I, Meignin V, Mebarki M, Rubio MT, Feugier P, Casasnovas O, Meignan M, and Thieblemont C

Subjects
Humans, Lactate Dehydrogenases, Positron Emission Tomography Computed Tomography, Prognosis, Retrospective Studies, T-Lymphocytes metabolism, Lymphoma, Large B-Cell, Diffuse diagnostic imaging, Lymphoma, Large B-Cell, Diffuse therapy, Lymphoma, Large B-Cell, Diffuse metabolism, Positron-Emission Tomography methods, Immunotherapy
Abstract

The aim of this study was to evaluate the prognostic impact of the F-fluorodeoxyglucose positron emission tomography response at 1 month (M1) and 3 months (M3) after anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a multicenter cohort of 160 patients with relapsed/refractory large B-cell lymphomas (R/R LBCL). In total, 119 (75%) patients reached M1 evaluation; 64 (53%, 64/119) had a complete response (CR); 91% were Deauville Score (DS) 1-3. Progressionfree survival (PFS) and overall survival (OS) were significantly worse in patients with DS-5 at M1, than in patients with DS 1-3 (PFS hazard ratio [HR]=6.37, 95% confidence interval [CI]: 3.5-11.5 vs. OS HR=3.79, 95% CI: 1.7-8.5) and DS-4 (PFS HR=11.99, 95% CI: 5.0-28.9 vs. OS HR=12.49, 95% CI: 2.8-55.8). The 1-year PFS rates were 78.9% (95% CI: 58.9-89.9) for DS-4 at M1, similar to 67.3% (95% CI: 51.8-78.8) for patients with DS 1-3 at M1, very different to 8.6% (95% CI: 1.8-22.4) for DS-5, respectively. Only eight of 30 (26%) patients with DS-4 progressed. Response at M3 evaluated in 90 (57%) patients was prognostic for PFS with lower discrimination (HR=3.28, 95% CI: 1.5-7.0; P=0.003) but did not predict OS (HR=0.61, 95% CI: 0.2-2.3; P=0.45). Patients with a high baseline total metabolic tumor volume (TMTV) >80 mL had worse PFS (HR=2.05, 95% CI: 1.2-3.5; P=0.009) and OS (HR=4.52, 95% CI: 2.5-8.1; P<0.001) than patients with low TMTV. Multivariable analyses identified baseline elevated lactate dehydrogenase, DS-5, CAR T cells at M1 for PFS and baseline elevated lactate dehydrogenase, TMTV >80 mL, and DS-5 at M1 for OS. In conclusion, baseline TMTV and response at M1 strongly predicts outcomes of patients with R/R LBCL undergoing CAR T-cell therapy.

Published
2023
Full Text
View/download PDF

29. Predictors of pneumocystosis or tuberculosis in HIV-infected Asian patients with AFB smear-negative sputum pneumonia.

Author

Le Minor O, Germani Y, Chartier L, Lan NH, Lan NT, Duc NH, Laureillard D, Fontanet A, Sar B, Saman M, Chan S, L'Her P, Mayaud C, and Vray M

Subjects
AIDS-Related Opportunistic Infections epidemiology, Adult, Cambodia epidemiology, Cohort Studies, Female, Humans, Logistic Models, Male, Pneumonia, Pneumocystis epidemiology, Pneumonia, Pneumocystis etiology, Predictive Value of Tests, Sputum microbiology, Tuberculosis, Pulmonary epidemiology, Vietnam epidemiology, AIDS-Related Opportunistic Infections diagnosis, HIV Infections complications, Pneumonia, Pneumocystis diagnosis, Tuberculosis, Pulmonary diagnosis
Abstract

Objectives: To identify predictors of Pneumocystis jiroveci pneumonia (PCP) or pulmonary tuberculosis (TB) in acid-fast bacillus smear-negative HIV-infected patients and to develop clinical prediction rules., Design: A cohort study conducted in consecutive hospitalized Asian patients., Methods: Multivariate analyses were performed on the Cambodian sample to determine clinical, radiological, and biological predictors of PCP or TB at hospital admission. The Vietnamese sample was kept for independent validation., Results: In Cambodia, the gold standard technique for TB and PCP were fulfilled in 172 (27 cases) and 160 (84 cases) patients, respectively. For TB, independent predictors included the following: headache [odds ratio (OR) 3.0; 95% confidence interval (CI) 1.04 to 8.6], localized radiological opacity (OR 5.8; 95% CI 1.9-17.9), and mediastinal adenopathy (OR 10.1; 95% CI 3.5 to 29.0); and for PCP: resting oxygen saturation <90% (OR 3.3; 95% CI 1.3 to 8.5 for resting arterial oxygen saturation >or=80%; and OR 9.1; 95% CI 1.8 to 44.5 for resting arterial oxygen saturation <80%), trimethoprim-sulphamethoxazole prophylaxis (OR 0.1; 95% CI 0.04 to 0.6), and diffuse radiological shadowing (OR 7.0; 95% CI 2.7 to 18.6). PCP risk predicted by a score based on these 3 factors ranged from 3% to 92% (Cambodia). When tested on Vietnamese patients (n = 69, 38 with PCP), the score maintained correct predictive ability (c-index = 0.72) but with poor calibration., Conclusions: The PCP score could provide a useful clinical tool to identify PCP among acid-fast bacillus smear-negative pneumonia and start specific therapy.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results